Skye Bioscience, Inc. Common Stock (SKYE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.83M
Last updated: Nov 17, 2026 at 11:03 AM ET
Skye Bioscience, Inc. Common Stock (SKYE) Stock Forecast
Analysts expect Skye Bioscience, Inc. Common Stock (SKYE) to earn -$5.04 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 2 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$6.67.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 50.0% |
| Hold | 2 | 50.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$5.04
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$6.67
- EPS consensus
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$5.04 | -$5.04 to -$5.04 | 1 |
| Dec 31, 2027 | -$6.67 | -$10.80 to -$4.56 | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.09 | -$1.18 to -$0.92 | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$8.37.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.04 | -$5.04 | -$5.04 | -$5.04 | -$8.37 | N/A |
| Fiscal year ending Dec 31, 2027 | -$6.67 | -$7.40 | -$7.40 | -$7.40 | -$9.05 | N/A |
Frequently Asked Questions About SKYE
What is the SKYE stock forecast?
Consensus analyst estimates put Skye Bioscience, Inc. Common Stock's EPS at -$5.04 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Hold.
How do analysts rate SKYE stock?
Of 4 analysts covering Skye Bioscience, Inc. Common Stock, 0 rate it Strong Buy, 2 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from SKYE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.04, with estimates from -$5.04 to -$5.04 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$6.67, with estimates from -$10.80 to -$4.56 from 3 analysts.
How many analysts cover SKYE?
4 analysts rate Skye Bioscience, Inc. Common Stock stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
SKYE pages: Overview, Earnings, Forecast, Financials, Competitors